Exactly. If PRO-140 can stand on its mono feet, you're looking at a multiple billion dollar market which makes dilution in the 10s of millions of shares not as hurtful to the potential multiple one could get on a BO. If the drug can only prove its use through combination therapy, the market is still in the 100s of millions/year.
News 
Market Data 
Discover 
AI
